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Summary
Background: Polymorphisms in genes involved in the atherosclerosis development, angiogenesis, and homocysteine 
(Hcy) metabolism could be risk factors for coronary artery disease (CAD).
Objective: To evaluate the effect of the VEGF C-2578A and MTHFR C677T polymorphisms on CAD, and the association 
of these polymorphisms with the severity and extension of atherosclerotic lesions and Hcy concentrations.
Methods: Two hundred and forty-four subjects were evaluated by coronary angiography and included in the study 
(145 with CAD and 99 controls). The VEGF C-2578A and MTHFR C677T polymorphisms were investigated by the PCR-
SSCP and PCR-RFLP techniques, respectively. Plasma Hcy was quantified by liquid chromatography/sequential mass 
spectrometry (LC-MS/MS).
Results: There was no significant difference in allele and genotype distribution between the groups, for both 
polymorphisms. The univariate analysis showed a higher frequency of the VEGF -2578AA genotype in the group with 
three-vessel disease (p=0.044). In addition, the VEGF -2578CA genotype was observed more frequently among individuals 
with <95% stenosis (p=0.010). After adjustment for other risk factors for CAD in a multivariate model, the VEGF C-
2578A polymorphism was not found to be an independent correlate of CAD (p=0.688). The MTHFR polymorphism did 
not show any association with the extension and/or severity of the CAD. The MTHFR C677T polymorphism showed no 
direct association with hyperhomocysteinemia or increased mean plasma concentrations of Hcy.
Conclusion: Although there is an apparent association between VEGF C-2578A and the development of coronary 
atherosclerosis, this association is not independent of conventional cardiovascular risk factors. (Arq Bras Cardiol 
2009;92(4):249-254)
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Alterations in the VEGF concentrations can be mediated 
by genetic polymorphisms7,8. Several single nucleotide 
polymorphisms (SNPs) have been described in the VEGF gene. 
Renner et al7 described three polymorphisms of the VEGF 
gene (C702T, C936T and G1612A) and observed significantly 
lower VEGF plasma levels in 936T allele carriers compared to 
non-carriers. The C702T and G1612 polymorphisms showed 
no association with VEGF levels. Elevated levels were also 
associated with the G allele in the VEGF -1154 nucleotide8. 
In a study with patients undergoing coronary angiography, 
the C-2578A polymorphism was considered a risk factor 
for atherosclerosis development1. This genetic variation had 
already been associated with lower VEGF expression8.
Hyperhomocysteinemia, i.e., increased blood homocysteine 
(Hcy) concentrations, is considered an independent risk 
factor for atherosclerosis and coronary artery disease (CAD)9. 
Increased Hcy concentrations are found in 40% of patients 
with coronary, cerebral or peripheral artery diseases, and only 
in 15% of healthy individuals10. The mechanism by which 
Introduction
The gene encoding the vascular endothelial growth factor 
(VEGF) has been studied in the development of coronary 
diseases1-3. VEGF, present in the vessel walls, promotes the 
proliferation of vascular endothelial cells and angiogenesis, 
but its role in atherosclerosis is still obscure. There are studies 
pointing to VEGF as a protection factor in the atherosclerotic 
plaque development, by acting as a regulator of the coronary 
artery wall endothelial integrity4,5. On the other hand, there are 
studies showing that neovascularization, mediated by VEGF, 
influences the pathogenesis of arterial diseases6.
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hyperhomocysteinemia induces the development of vascular 
lesions is still obscure. Experimental evidence suggests that 
Hcy may be involved in atherogenesis and thrombogenesis, 
leading to muscle cell hyperplasia and fibrosis10,11. Abnormal 
Hcy concentrations can result from the interaction of genetic 
and dietary factors12. The enzyme methylenetetrahydrofolate 
reductase (MTHFR), which plays an important role in the Hcy 
metabolism, presents decreased activity as a result of the 
polymorphism in the position 677 of the MTHFR gene, and 
leads to increased Hcy concentrations13. The variant allele 
MTHFR 677T has been found at high frequencies in patients 
with vascular diseases14-17.
In this study, we analyzed the frequency of the VEGF 
C–2578A and MTHFR C677T polymorphisms in patients with 
CAD and in a group without angiographic signs of the disease, 
and evaluated the association between these polymorphisms 
and the severity and extension of the atherosclerotic lesions, 
and the plasma Hcy concentrations.  
Methods
Study subjects
This study was approved by the National Research 
Commission - CONEP, DF, Brazil. After signing a free informed 
consent form, 244 Caucasoid individuals were included in 
the research (145 with CAD and 99 without the disease). The 
diagnosis of CAD was confirmed or ruled out by coronary 
angiography, analyzed by two independent observers in 
a quantitative blind analysis, performed at the Cath Lab. 
Individuals who had undergone heart surgery and those with 
a coronary prosthesis were excluded from the study. Although 
miscegenation is widespread in Brazil, we considered as 
Caucasoid those individuals who had no other ethnic groups 
in the three generations that preceded them18. The extension 
of the CAD was determined according the number of involved 
coronary vessels (0 to 3), and the CAD severity by the degree 
of arterial obstruction (<50%, >50-75%, >75-95%, and 
>95% stenosis). Ejection fraction (EF) < 40% was considered 
as ventricular damage. Typical angina was considered as 
present or absent. 
Classical risk factors for CAD were also investigated. 
The criteria used for defining diabetes were the use of oral 
hypoglycemic agents or insulin treatment, or glycemia levels 
higher than 126 mg/dl; for hypertension, the use of anti-
hypertensive medication or blood pressure higher than 140/90 
mmHg; for sedentary lifestyle, the absence of regular and 
controlled exercising; for alcoholism, the intake of alcohol 
with a frequency defined without a quantitative analysis; 
individuals who had smoked >100 cigarettes throughout their 
lifetime and currently smoked every day or on some days were 
considered smokers. 
Biochemical analysis
Peripheral blood samples were collected from the patients 
during the coronary angiographic examination, after a 12-hour 
fasting. Plasma separation was performed within one hour after 
blood collection for Hcy quantitation, according to the liquid 
chromatography/sequential mass spectrometry (LC-MS/MS) 
method19. Hcy concentrations >15µmol/ml were considered 
as characterizing hyperhomocysteinemia20.
The procedures for lipid profile determination were carried 
out at the Clinical Test Laboratory of the Base Hospital of the 
São José do Rio Preto Medical School. Serum triglycerides 
(TG), total cholesterol (TC), high-density lipoproteins (HDLC), 
and low-density lipoproteins (LDLC) were measured by the 
enzymatic colorimetric method. 
Genotype determination
Genomic DNA was extracted from peripheral blood 
leukocytes21. The VEGF C-2578A polymorphism was 
investigated by the Polymerase Chain Reaction-Single-
Strand Conformational Polymorphism (PCR-SSCP) method, 
according to Brogan et al22. Thirty amplification cycles (95oC 
for 30s, 62oC for 30s, and 72oC for 60s) were performed to 
amplify a 309 bp product. Then, 6 µl of the PCR product 
were denatured at 95oC for 5 min with 6 µl electrophoresis 
staining solution (80% v/v formamide; 10mM NaOH; 1 mM 
EDTA, pH 8.0; 0.1% w/v of bromophenol blue; and 1.1% 
xylenocyanol). The denatured products were analyzed by 
9.6% polyacrylamide gel electrophoresis and visualized after 
silver nitrate staining. 
Genotyping for the MTHFR C677T polymorphism was 
performed by PCR followed by enzyme digestion16. Thirty-
five cycles (94oC for 60s, 58oC for 60s, and 72oC for 60s) 
were performed to amplify a 198 bp product. The PCR 
products were digested with the restriction enzyme Hinf I 
and the fragments were analyzed on a 9.6% polyacrylamide 
gel stained with silver nitrate. Allele C was not digested, 
whereas allele T was cut into two fragments of 175 bp and 
23 bp, respectively.
Statistical analysis
Data are presented as mean ± standard deviation (SD) 
or number (percentages). Comparison between the groups 
was performed using the Chi-square, Student’s t-test or 
Mann-Whitney’s test, as appropriate. Dependence analysis 
was used to examine differences in genotype frequency 
between groups with one, two, or three affected arteries, 
and between groups with a different degree of stenosis The 
Hcy values were modeled based on a normal distribution 
on the logarithmic scale. Hcy concentration in relation to 
the MTHFR polymorphism was evaluated by analysis of 
variance (ANOVA). The independent relationship of the 
VEGF C-2578A and MTHFR C677T polymorphisms with risk 
factors in the presence of CAD was tested by multiple logistic 
regression analysis. A p-value ≤ 0.05 was used to establish 
statistical significance.
Financial support - The State of São Paulo Research 
Foundation (FAPESP).
Results
The characteristics of the studied population are shown in 
Table 1. The significantly different results obtained for patients 
with and without CAD are in agreement with previously 
established cardiovascular risk factors. 
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Vascular endothelial growth factor (VEGF) gene 
polymorphism
There was no significant difference between the groups 
regarding allele (p=0.995) and genotype (p=0.254) 
frequencies of the VEGF C-2578A polymorphism. Calculations 
for the Hardy-Weinberg equilibrium (HWE) test showed that 
the genotype distribution observed was similar to the expected 
one, in both CAD and control groups (x21=3.12; p=0.077 
and x21=0.46; p=0.496, respectively).
Genotype frequencies according to the number of involved 
vessels and degree of artery obstruction are shown in Tables 2 
and 3, respectively. A significantly higher frequency of VEGF 
-2578AA genotype was found in individuals with three affected 
arteries (p=0.044). Regarding the degree of artery obstruction, 
the VEGF -2578CA genotype was observed more frequently 
in individuals with <95% stenosis (p=0.010). 
Methylenetetrahydrofolate reductase (MTHFR) gene 
polymorphism and homocysteine concentrations 
There was no significant difference between the groups 
regarding allele (p=0.895) and genotype (p=0.884) 
frequencies of the MTHFR C677T polymorphism. The 
observed genotype distribution was similar to the expected 
one in the control group (x21=2.23; p=0.135), but it 
showed departure from the HWE in the CAD group, with a 
significant difference between the observed and the expected 
frequencies (x21=5.76; p=0.016). 
Table 1 - Characteristics of the study population
CAD Controls
p-value
(n = 145) (n = 99)
Age (years) 60.4±12.3 57.8±11.4 0.084
Gender 0.066
Males 93(64) 51(52)
Females 52(36) 48(48)
Hypertension 113(78) 66(67) 0.708
Diabetes 36(25) 13(13) 0.040
Sedentary lifestyle 63(43) 50(51) 0.339
Smoking 100(69) 52(53) 0.014
Angina 115(79) 68(69) 0.083
Ventricular damage 50(34) 14(14) 0.0007
Alcoholism 48(33) 25(25) 0.240
Total cholesterol (>200mg/dl) 60(41) 41(41) 0.996
HDLc (<40 mg/dl) 78(54) 31(31) 0.0008
LDLc (>130 mg/dl) 57(40) 36(36) 0.740
VLDLc (> 30 mg/dl) 58(40) 33(33) 0.356
Triglycerides (>150 mg/dl) 63(43) 36(36) 0.330
Values are presented as mean ± SD or number (%). CAD - Coronary artery 
disease; HDLc- high-density lipoprotein; LDLc - low-density lipoprotein; VLDLc 
- very-low-density lipoprotein.
Table 2 - Genotype frequencies in patients with one, two, and three 
affected arteries
Polymorphism
One 
affected 
artery
Two 
affected 
arteries
Three 
affected 
arteries
p-
value
N (%) N (%) N (%)
VEGF -2578
CC 15 (44) 14 (41) 5 (15)
0.044CA 32 (38) 28 (34) 23 (28)
AA 6 (21) 8 (29) 14 (50)
MTHFR 677
CC 24 (45) 16 (30) 13 (25)
0.548CT 25 (31) 29 (36) 26 (33)
TT 4 (33) 5 (42) 3 (25)
Table 3 - Genotype frequencies in patients with <50%, >50-75%, >75-
95%, and >95% stenosis
Polymorphism
Degree of stenosis
p-
value<50% >50-75% >75-95% >95%
N (%) N (%) N (%) N (%)
VEGF -2578
CC 2 (6) 6 (18) 16 (47) 10 (29)
0.010CA 9 (11) 17 (21) 45 (54) 12 (14)
AA 0 (0) 4 (14) 13 (47) 11 (39)
MTHFR 677
CC 4 (7) 10 (19) 27 (51) 12 (23)
0.991CT 6 (8) 16 (20) 41 (51) 17 (21)
TT 1 (8) 1 (8) 6 (50) 4 (34)
No association was observed between the MTHFR C677T 
polymorphism and the number of involved vessels and/or the 
degree of artery obstruction (Tables 2 and 3). 
The mean Hcy concentration did not significantly differ 
between the groups (p=0.222), nor did the presence 
of hyperhomocysteinemia (p=0.266). The mean Hcy 
concentrations did not show any association with the 
number of involved vessels (p=0.793) or the degree of artery 
obstruction (p=0.700).
The MTHFR C677T polymorphism showed no direct 
association with hyperhomocysteinemia (p=0.860) or 
increased mean concentrations of Hcy (p=0.758).
Multivariate analysis
Multiple logistic regression was used to test independent 
correlates for the presence of CAD. The model included: 
smoking, hypertension, diabetes, HDLc levels, and the VEGF 
C-2578A and MTHFR C677T polymorphisms. Smoking 
(p=0.006), diabetes (p=0.041), and HDLc levels <40 mg/dl 
(p=0.0008) were independent correlates of the presence of 
CAD. Hypertension tended towards showing an association 
with CAD (p=0.061). The VEGF C-2578A (p=0.688) 
and MTHFR C677T (p=0.981) polymorphisms were not 
independent predictors of CAD.
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Discussion
In our study, the allele and genotype frequencies of 
the VEGF C-2578A polymorphism did not differ between 
patients with and without CAD. However, the VEGF -2578AA 
genotype was observed at a higher frequency in individuals 
with three affected arteries. This result corroborates the 
findings of a recent study by Howell et al1, in which the 
VEGF -2578AA genotype was considered to be a risk factor 
for atherosclerosis development, whereas the VEGF -2578CC 
genotype showed a protective effect. According to this study, 
the frequency of the VEGF -2578AA genotype gradually 
increased with the number of involved vessels, as compared 
to the wild-type VEGF -2578CC genotype, suggesting that 
the reduction in the VEGF expression resulting from the 
VEGF -2578AA genotype could promote the development of 
atherosclerosis. The higher frequency of the VEGF -2578CA 
genotype among individuals with <95% stenosis suggests an 
association between this genotype and the slower progression 
of the atherosclerotic lesion, possibly due to the presence 
of the wild-type allele. However, no association was found 
regarding the wild-type VEGF -2578CC genotype, possibly 
because of the small sample size. 
Although our results regarding VEGF polymorphism and the 
severity and extension of CAD were significant, after adjustment 
for other risk factors in a multivariate model, the positive 
association between VEGF C-2578A polymorphism and severity 
or extension of CAD lost statistical significance. Since VEGF C-
2578A polymorphism was not an independent risk factor for 
CAD, these data do not support a casual linkage between VEGF 
C-2578A polymorphism and coronary atherosclerosis.
The role of VEGF in atherosclerosis is a subject of debate 
in the literature. Some studies showed that the administration 
of recombinant human VEGF in animals enhances the 
progression of the atherosclerotic plaque23, whereas others 
observed that it acts as an anti-atherosclerotic factor, 
promoting re-endothelization, reducing intimal thickening 
and preventing thrombus formation5.
 Correlations between genotypes and expression were 
not examined in our study. However, a study by Shahbazi 
et al8, with renal transplant recipients, found an association 
between the wild-type allele VEGF -2578C and increased 
VEGF concentrations. Other polymorphisms of the VEGF 
gene have already been associated with variations in the 
expression of the protein7,8. According to Howell et al1, 
the VEGF -2578AA genotype could be considered a risk 
factor for atherosclerosis due to the reduction in the protein 
expression. This result is consistent with the action of VEGF 
in the endogenous regulation of the endothelial integrity of 
the coronary artery wall4. On the other hand, atherosclerotic 
plaque neovascularization, mediated by VEGF, makes 
nutrients and components for the plaque available, 
increasing its volume.  In artery walls with total occlusion 
by atherosclerotic plaques, as observed in a prospective 
study, microvessels named vasa vasorum were correlated, in 
their anatomy and quantity, to the degree of intimal plaque 
inflammation24. Moulton et al25 observed a reduction in 
atherosclerosis progression secondary to the inhibition of 
VEGF-mediated neovascularization. Thus, further studies are 
necessary to clarify the true role of VEGF in CAD. 
In this study, the allele and genotype frequencies of the 
MTHFR C677T polymorphism did not differentiate patients from 
controls. However, in the CAD group, the genotype distribution 
observed was different from the one expected according to 
the Hardy-Weinberg equilibrium (HWE). Case-control studies 
with SNP analysis have shown departure from HWE in patients, 
in controls or in both groups26-28. This disequilibrium can 
be expected for a number of genetic diseases, considering 
that there probably is a significant genetic contribution in 
complex diseases29. Although some studies found evidence 
of an association between the polymorphic MTHFR 677T 
allele and vascular diseases, carotid atherosclerosis, occlusive 
arterial disease and myocardial infarction15-17,30-32, others did 
not confirm these hypotheses11,33. 
A b o u t  4 0 %  o f  p a t i e n t s  w i t h  C A D  p r e s e n t 
hyperhomocysteinemia34. In our study, 49.7% of the 
patients with CAD and 45.2% of the controls showed Hcy 
concentrations >15 µmol/L, and this difference was not 
significant. Another Brazilian study showed a significant 
difference in Hcy concentrations between the control group 
and a group with severe atheromatosis. These authors also 
observed a positive correlation between higher Hcy levels and 
CAD35. In our study, higher Hcy mean concentrations were 
found in the CAD group compared to the control group, but 
the difference was not significant (data not shown), which is 
in agreement with the findings of Yilmaz et al36.
 Clinical trials involving homocysteine-lowering treatment 
have demonstrated that folate supplementation did not reduce 
the risk of complications and death due to cardiovascular 
causes, despite a substantial reduction in plasma total Hcy 
levels37,38. Although observation studies have demonstrated 
that the plasma total Hcy level is a predictor of cardiovascular 
events39, no causative role of Hcy has been substantiated 
by the results of intervention trials involving homocysteine-
lowering treatment.
In the prospective study of Frederiksen et al40, the Hcy 
mean concentration was higher in MTHFR 677TT genotype 
carriers compared to the carriers of other genotypes; however, 
the MTHFR C677T polymorphism was not associated with 
ischemic cardiovascular disease or thromboembolism. Similar 
observations were reported by Huh et al41 and Yilmaz et al36 
in CAD studies. In the population studied by us, the MTHFR 
C677T polymorphism did not present a direct association 
with hyperhomocysteinemia or increased mean Hcy 
concentrations, either in the CAD or in the control group. 
A correlation between the presence of this mutation and 
hyperhomocysteinemia was also not observed by Lima et al35, 
in another Brazilian study.
Sample size is an important factor in case-control studies, 
mainly in investigations of genetic polymorphisms with high 
frequency in the general population. Although the number 
of individuals evaluated in this study was sufficient to 
demonstrate a statistical difference in genotype distribution 
among the subgroups with different degrees of artery 
obstruction and number of involved vessels, no difference 
was observed between the CAD and control groups. Studies 
in the literature use larger samples, mainly to evaluate the 
association between polymorphisms and CAD or Hcy. 
Moreover, the investigation of alterations in other enzymes 
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involved in Hcy metabolism, plasma folate and vitamin B6 
and B12 concentrations, and vitamin intake, could provide 
more consistent data for the discussion about the effect of 
polymorphisms on Hcy concentrations.
In summary, there is an apparent association between 
the VEGF C-2578A polymorphism and atherosclerosis 
development; however, this association is not independent 
of conventional cardiovascular risk factors.
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